Liver Cancer
Conditions
Brief summary
This study is to evaluate whether intraoperative fluorescence imaging using fluorescent-labeled IgG probe (FluoAB) can help distinguish the tumor and the liver cirrhosis (or the liver parenchyma). The main purposes of this study include: * To validate the safety and effectiveness of using FluoAB in hepatic surgery. * To raise the surgical precision with guidance by FluoAB fluorescence imaging.
Interventions
DRUGFluoAB
Drug Injection: FluoAB (fluorescent-labeled IgG)
Sponsors
Chinese Academy of Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who have been diagnosed with liver tumor. 2. Planned to receive hepatectomy. 3. Liver function Child-Pugh A/B. 4. The expected lifetime is longer than 6 months. 5. Approved to sign the informed consent.
Exclusion criteria
1. Enrolled in other trials in the past 3 months. 2. Metastatic lesions were found. 3. Undesirable function of heart, lung, kidney, or any other organs. 4. Unable to tolerate a hepatectomy. 5. The researchers considered inappropriate to be included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor imaging precision | Update with an average of 2 weeks. | Sensitivity and specificity of hepatic malignancy detection by fluoAB intraoperative imaging. |
| Tumor lesions | Immediately after the hepatic surgery. | Numbers of intraoperatively detected tumor lesions. |
Countries
China
Contacts
Primary ContactZeyu Zhang, Ph.D.
Outcome results
None listed